Global Overview of the Pharmaceuticals and Medical Equipment Industry

Delivery

This report comes in PPT.

Key findings

Rising investment in R&D and innovation

Ageing populations and the rising prevalence of chronic diseases will continue to fuel demand for high-value innovative treatments, and drive investment in research and development (R&D), especially in the areas of oncology, immunology, neurology, cardiovascular and metabolic disorders. Biologics are set to remain among the fastest growing categories, with the rising importance of treatment personalisation.

Supply chain transformation

In the wake of the pandemic and the war in Ukraine, many countries have faced disruptions in supply of active pharmaceutical ingredients (API) and other medicines and medical devices. Governments’ efforts to improve supply chain resilience are expected to facilitate alternative supply arrangements and localisation of production of pharmaceuticals and essential medical devices.

Innovative production methods and digitalisation

Pharmaceutical producers are embracing new production methods, such as continuous manufacturing, single-use technologies and modular solutions, to save costs and time, and increase reliability. Moreover, a greater focus on smart production transformation, including digitalisation of manufacturing, automation and robotisation, will contribute to future industry progress.

Cost-conscious environment

Under the rising pressure to reduce healthcare costs, growing pharmaceuticals pricing pressure will continue to squeeze producers’ margins. It is also set to drive up demand for generics and biosimilars, foster early diagnostics to improve preventative health and facilitate a shift towards value-based pharmaceutical contracts.